RXRX Recursion Pharmaceuticals, Inc.

$3.20▲ +1.27% Healthcare Other
After hours $3.20▲ +0.00% Sep 11, 7:58 PM ET
Volume 8.01M Avg Volume (10D) 14.21M
Key Metrics & Fundamentals
Market Cap
$1.72B
P/E Ratio
–
Div Yield
–%
52W Range
2.77 - 7.18
% vs 50 MA
-2.92%
% vs 200 MA
-11.86%
RSI-14
45.9
MACD Histogram
-0.0300
Beta (1Y vs SPY)
2.90
Free Cash Flow
-$107.91M
Gross Rev
$7.30M
Gross Profit
-$4.19M
EBITDA
-$112.53M
COGS
$11.49M
Operating Exp
$130.78M
Operating Income
-$134.97M
EBIT
-$134.97M
Pretax Income
-$131.01M
Net Income
-$131.01M
EPS (Diluted)
-0.25
Price & Volume History
Loading chart…
Recent News
Why Recursion Pharmaceuticals (RXRX) Dipped More Than Broader Market Today
Zacks · Sep 10, 2026 9:50 PM
2 Beaten-Down Stocks to Avoid Right Now
Motley Fool · Sep 8, 2026 6:20 PM
Why Is Recursion Pharmaceuticals (RXRX) Up 8.2% Since Last Earnings Report?
Zacks · Sep 4, 2026 3:30 PM
Can RXRX's Pipeline Expansion Strengthen Its Long-Term Growth Outlook?
Zacks · Sep 3, 2026 2:32 PM
The Zacks Analyst Blog Highlights Recursion Pharmaceuticals, Schrodinger, Relay Therapeutics and Absci
Zacks · Aug 18, 2026 7:43 AM
Contineum, Disc Medicine, Recursion Advance Pipelines Ahead of Catalysts, Morgan Stanley Says
MT Newswires · Aug 17, 2026 3:01 PM
4 AI-Powered Drug Discovery Stocks to Watch as AI Reshapes Pharma
Zacks · Aug 17, 2026 1:56 PM
Morgan Stanley Adjusts PT on Recursion Pharmaceuticals to $5.30 From $5.50, Keeps Equalweight Rating
MT Newswires · Aug 17, 2026 9:54 AM
Recursion Pharmaceuticals Highlights AI Platform, Roche Progress and Pipeline Updates
MarketBeat · Aug 17, 2026 5:01 AM
These Are the Stocks Wall Street Is Betting Against the Most
GuruFocus.com · Aug 12, 2026 7:30 PM
Financial Overview - Income Statement Quarterly

See RXRX's money flow as a full page

Social Sentiment
Avg +0.78 · 63 posts
DiscussionAdvice for my teenager's plans?
r/stocks · Jul 19, 2026
Company discussed with a defined allocation within the portfolio plan.
positive +0.60
DDNewsThis might go to the moon
r/options · Jul 1, 2026
The author describes Recursion's technology as a revolutionary approach to drug discovery and highlights its large dataset and AI capabilities – indicating strong belief in the company’s future.
positive +0.80
NewsDiscussionTelling yall rxrx to the moon
r/options · Jul 1, 2026
The post expresses a strong belief in RXRX's growth potential ('to the moon') and highlights key partnerships and investment.
very_positive +1.00
TradeDiscussionDDPharma AI - might still be too early
r/wallstreetbets · May 4, 2026
The author highlights positive aspects of the company like AI drug discovery and significant backing. They describe it as an ‘AI-first’ play.
positive +0.70
DDNewsTrade$RXRX: The AI Bio-God of 2026 or Why You’re a Moron for Buying Overpriced Index Funds
r/wallstreetbets · Feb 18, 2026
Strong bullish sentiment, framing the stock as a 'monster' and criticizing those buying index funds.
positive +0.80
Page 1 of 13 (63 total)
AI Analysis

Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.

Not financial advice. All data, scores, charts, and analysis on this site are provided for informational and educational purposes only and do not constitute financial, investment, legal, or tax advice. Past performance is not indicative of future results. See our Legal Notice for full details.
An unhandled error has occurred. Reload 🗙